Related Experiment Video
Updated: Oct 22, 2025

In Vitro Analysis of E3 Ubiquitin Ligase Function
Published on: May 14, 2021
CHIP/STUB1 Ubiquitin Ligase Functions as a Negative Regulator of ErbB2 by Promoting Its Early Post-Biosynthesis
Haitao Luan1,2,3, Tameka A Bailey1, Robert J Clubb1
1Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Abstract:
Overexpression of the epidermal growth factor receptor (EGFR) family member ErbB2 (HER2) drives oncogenesis in up to 25% of invasive breast cancers. ErbB2 expression at the cell surface is required for oncogenesis but mechanisms that ensure the optimal cell surface display of overexpressed ErbB2 following its biosynthesis in the endoplasmic reticulum are poorly understood. ErbB2 is dependent on continuous association with HSP90 molecular chaperone for its stability and function as an oncogenic driver. Here, we use knockdown and overexpression studies to show that the HSP90/HSC70-interacting negative co-chaperone CHIP (C-terminus of HSC70-Interacting protein)/STUB1 (STIP1-homologous U-Box containing protein 1) targets the newly synthesized, HSP90/HSC70-associated, ErbB2 for ubiquitin/proteasome-dependent degradation in the endoplasmic reticulum and Golgi, thus identifying a novel mechanism that negatively regulates cell surface ErbB2 levels in breast cancer cells, consistent with frequent loss of CHIP expression previously reported in ErbB2-overexpressing breast cancers. ErbB2-overexpressing breast cancer cells with low CHIP expression exhibited higher endoplasmic reticulum stress inducibility. Accordingly, the endoplasmic reticulum stress-inducing anticancer drug Bortezomib combined with ErbB2-targeted humanized antibody Trastuzumab showed synergistic inhibition of ErbB2-overexpressing breast cancer cell proliferation. Our findings reveal new insights into mechanisms that control the surface expression of overexpressed ErbB2 and suggest that reduced CHIP expression may specify ErbB2-overexpressing breast cancers suitable for combined treatment with Trastuzumab and ER stress inducing agents.
Insights
The C-terminus of HSC70-Interacting protein (CHIP) degrades overexpressed ErbB2 (HER2) in breast cancer cells. Loss of CHIP increases ErbB2, making cancers responsive to combined Trastuzumab and endoplasmic reticulum stress therapies.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Overexpression of ErbB2 (HER2) drives oncogenesis in a significant portion of invasive breast cancers.
- Cell surface expression of ErbB2 is crucial for its oncogenic activity, but the mechanisms regulating its display are not fully understood.
- ErbB2 stability and function depend on the HSP90 molecular chaperone.
Purpose of the Study:
- To investigate the role of CHIP (C-terminus of HSC70-Interacting protein) in regulating cell surface ErbB2 levels.
- To identify novel mechanisms controlling ErbB2 cell surface expression in breast cancer.
- To explore therapeutic strategies targeting ErbB2-overexpressing breast cancers with reduced CHIP expression.
Main Methods:
- Utilized knockdown and overexpression studies to assess CHIP's effect on ErbB2.
- Investigated the ubiquitin/proteasome-dependent degradation pathway in the endoplasmic reticulum and Golgi.
- Analyzed endoplasmic reticulum stress responses in breast cancer cells with varying CHIP expression levels.
- Evaluated the synergistic effects of Bortezomib and Trastuzumab on cancer cell proliferation.
Main Results:
- CHIP targets newly synthesized, HSP90/HSC70-associated ErbB2 for degradation, thereby negatively regulating cell surface ErbB2 levels.
- Loss of CHIP expression in ErbB2-overexpressing breast cancers correlates with increased endoplasmic reticulum stress.
- Combined treatment with Bortezomib and Trastuzumab demonstrated synergistic inhibition of ErbB2-overexpressing breast cancer cell proliferation.
Conclusions:
- CHIP acts as a novel negative regulator of cell surface ErbB2 expression in breast cancer.
- Reduced CHIP expression may identify ErbB2-overexpressing breast cancers that are sensitive to combined Trastuzumab and endoplasmic reticulum stress-inducing agents.
- These findings offer new insights into ErbB2 regulation and suggest a potential therapeutic approach for specific breast cancer subtypes.
Related Concept Videos
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Hedgehog Signaling Pathway
Export of Misfolded Proteins out of the ER
Regulation of the Unfolded Protein Response
Negative Regulator Molecules

